SEC Form 4 · accession 0001209191-15-038191
Anacor Pharmaceuticals, Inc. · ANAC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kirk R Maples
Officer — SVP, Program Management
Period of report
May 1, 2015
Accepted (ET)
May 1, 2015 · 7:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001411158
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 1, 2015 | S | 100 | $52.99 | D | 8,320 | D | |
| Common StockF2 | May 1, 2015 | S | 500 | $54.142 | D | 7,820 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This sale was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.96 to $54.38, inclusive.